bpc-157 fda warning august 2025 On 15 2025, the U.S. Food & Drug Administration (FDA) issued a Letter to Platinum Biologics LLC for marketing umbilical‑cord‑derived products including exosome products (“NanoEx” & “Nano Xsomes”) without approval This Week at FDA: New

Description BPC-157 Peptide (5mg/ml Autoinjector Pen): The 2026 Research Guide If you are researching BPC-157 peptide , this page explains what the pentadecapeptide is, how it is studied in preclinical models, how it compares to TB-500, and exactly how PrymaLab supplies it a preloaded 3ml autoinjector pen at 5mg/ml intended strictly for in-vitro and non-human laboratory research

There's an advisory committee meeting on July 23, 2026 about adding it to the 503A Bulks List for wound healing

Unlike other peptides like TB-500, BPC-157 has a unique origin and mechanism of action that targets connective tissue repair directly

Psychiatry 81 , 411423 (2017)

For product evaluation, the practical questions are copper-complex identity, chromatographic purity, lot traceability, and agreement among the COA, HPLC, MS, and compound reference

In rat wound healing studies, collagen synthesis increased 9-fold with peptide-incorporated collagen dressings